WHO: Ending TB will take greater political commitment
Health experts warned that progress to end tuberculosis has stalled and that greater political commitment is needed to address the burden of the world’s No. 1 infectious disease killer.
There were 10.4 million new TB infections in 2016, with 10% occurring in patients who also have HIV, according to a new WHO report outlining the burden. Around 1.7 million people died from the disease, including nearly 400,000 patients who were coinfected with HIV.
WHO has adopted a strategy to end the TB epidemic by 2030.
“The sheer numbers show that we are not accelerating fast enough. That’s the big message. We need to do much more,” Mario Raviglione, MD, director of WHO’s Global Tuberculosis Programme, said during a teleconference today. “The main solution remains a political one. We need attention that goes beyond ministers of health.”
Experts hope two upcoming meetings will intensify the spotlight on TB. Next month, the disease will be the focus of a WHO conference in Moscow that Raviglione said will be attended by representatives from 100 countries. That will be followed by a U.N. General Assembly high-level meeting in 2018 that will seek a greater commitment from heads of state on TB.
It will be just the fifth time in the history of the U.N. that a global health topic has been discussed at the General Assembly, including last year’s high-level meeting on antimicrobial resistance. In a statement, WHO Director-General Tedros Adhanom Ghebreyesus, PhD, MSc, said the meeting in Moscow and at U.N. headquarters will “build momentum” to end TB at a global level.
According to the WHO report, there has been a 37% decline in TB mortality since 2000. But the agency noted several “grim” statistics, including that TB is the leading cause of death related to antimicrobial resistance and the leading killer among patients with HIV.
The report outlined several main areas of concern, including what it said is an estimated 4.1 million “missing” cases of TB worldwide — patients who have not been detected, diagnosed or reported. Three countries — India, Indonesia and Nigeria — account for nearly half of these infections, according to the report. Raviglione said large, unregulated private sectors in these countries might be treating cases but not reporting them.
“We do not know exactly what is going on — if the cases exist, do not exist, if they are treated properly or not treated properly,” he said. “There is concern that it might even create the conditions for drug resistance.”
According to the report, in 2016, there were an estimated 600,000 new cases of TB with resistance to the key first-line drug rifampin, including 490,000 multidrug-resistant infections (MDR-TB). Only around 20% of these patients were started on appropriate treatment — a global gap that is particularly a problem in China and India.
Even when MDR-TB is detected and diagnosed, patients face a significant challenge. In 2016, just 54% of them experienced treatment success, according to the report.
Although a majority of patients with TB worldwide are tested for HIV, 15% of coinfected patients are not put on antivirals as recommended, a gap that is especially seen in Africa, according to the report.
The report highlighted the need to increase preventive treatment in two priority risk groups: people living with HIV and children aged younger than 5 years. It said most patients eligible for TB preventive treatment are not accessing it.
Gaps in funding, research
According to the report, investment in TB care and prevention in low- and middle-income countries falls around $2.3 billion short of the $9.2 billion that is needed in 2017. Shortfalls also exist in funding for new vaccines, diagnostics and medicines, the report said.
It names 10 high-burden countries — India, Indonesia, Nigeria, the Philippines, South Africa, Pakistan, Bangladesh, the Democratic Republic of the Congo, China and Tanzania — where progress is particularly needed. Seven of these countries accounted for 64% of the total TB burden in 2016, with India at the top.
“It’s TB’s time,” Eric Goosby, MD, the U.N. special envoy for TB, said during the teleconference. “We can make this leading infectious disease killer a killer that has a cure and use every tool we have to defeat it.”
Raviglione said funding for TB research and development should match the investment made for HIV that has produced so many antivirals over the past several decades.
“What is the common denominator on all of these challenges to be addressed? It’s political commitment and investment,” Raviglione said. “If we want to face tuberculosis the way we should face it, we should invest much more.” – by Gerard Gallagher
WHO. Global tuberculosis report 2017. http://www.who.int/tb/publications/global_report/en/. Accessed October 30, 2017.
Disclosures: Goosby, Raviglione and Tedros report no relevant financial disclosures.